Kerendia, also known by its generic name finerenone, is a prescription medication used primarily for the treatment of chronic kidney disease (CKD) in patients with type 2 diabetes. As a non-steroidal, selective mineralocorticoid receptor antagonist, Kerendia works by blocking the action of aldosterone, a hormone that can contribute to kidney and cardiovascular damage over time. By mitigating the effects of aldosterone, this medication helps protect the kidneys from further damage, potentially slowing the progression of CKD and reducing the risk of associated cardiovascular events. Kerendia is typically prescribed as part of a comprehensive treatment plan that may also include diet, exercise, and other medications to manage diabetes and kidney disease effectively.